Atherectomy Devices Market | Global Industry Analysis 2033

Atherectomy Devices Market Overview

Global Atherectomy Devices Market size is projected at USD 1146.53 million in 2024 and is expected to hit USD 1562.6 million by 2033 with a CAGR of 3.5%.

The global atherectomy devices market reached a value of approximately USD 1.02 billion in 2024 and was estimated at around USD 1.04 billion in 2025 . In 2021, the market was valued at USD 1.06 billion, highlighting a broad range of historical values . North America held the largest single regional share of 42 percent in 2024, estimated at USD 440 million to USD 440 million, and represented some 41–42 percent share through 2024 .

Asia-Pacific showed the fastest expansion, with roughly 114 million PAD cases in the region by 2022 and a rapidly increasing disease burden . Directional atherectomy held around 35.9 percent market share in 2022, while rotational, orbital, and laser atherectomy segments comprised the remainder . Single-procedure success rates for atherectomy often exceed 90 percent; for instance, orbital atherectomy showed ~90 percent success and laser atherectomy ~76 percent in real-world studies .

Key Findings

Top Driver Reason: Rising incidence of peripheral artery disease (over 200 million cases globally in 2022; ~6.5 million in the U.S.) is fueling demand.

Top Country/Region: North America remains the leading region with approximately 42 percent of the market share in 2024 (around USD 440 million).

Top Segment: Directional atherectomy accounted for approximately 35.9 percent of the total market in 2022.

Atherectomy Devices Market Trends

The global atherectomy devices market demonstrated a significant presence in 2024, with reported market sizes ranging from USD 1,022.4 million to USD 1,230 million . North America retained dominance as the largest regional market, accounting for approximately USD 993 million in 2024—about 97 percent of the regional total . Asia‑Pacific emerged as the fastest growing region, contributing roughly USD 114 million in PAD cases by 2022 and showing rapid uptake .

In terms of technology segmentation, directional atherectomy remained the leading type, commanding close to 35.9 percent share in 2022 . The laser atherectomy subsegment showed strong growth momentum, with approximately 24 percent of procedures in 2021, supported by rapid technological advancements . Rotational atherectomy held a leading position globally in 2023 due to its effectiveness with calcified lesions, while orbital atherectomy demonstrated around 90 percent procedural success in real-world data .

Hospitals and surgical centres maintained dominance with a revenue share of approximately 60 percent in 2021, benefitting from advanced infrastructure and referral networks . Peripheral vascular applications led adoption, representing the fastest-growing application area due to rising PAD prevalence . The cardiovascular and neurovascular segments also contributed, supported by minor but steady increases in coronary atherectomy procedures valued at USD 210 million in 2024 and planned USD 230 million in 2025 .

Key drivers defining market trends included a growing preference for minimally invasive procedures (MID) and expanding geriatric demographics. Reports showed a shift toward orbital and laser systems, attributed to reduced vessel trauma and faster patient recovery . Technological integration is advancing through image-guided systems such as the 510(k)–submitted Avinger system in early 2023 .

Market restraint factors include device cost; laser systems are notably more expensive than standard angioplasty, prompting concerns over reimbursement . The atherectomy sector also faced criticism over its invasive nature and limited randomized‑control evidence compared to angioplasty-only procedures .

Emerging trends spotlight the adoption of robotic navigation and AI-assisted systems to improve procedural accuracy and reduce radiation exposure for operators . Image guidance and combination therapies (atherectomy coupled with drug-coated balloons) are increasing, particularly in neurovascular and coronary applications .

Overall, the atherectomy market in 2024–2025 is characterized by strong directional dominance, robust momentum in laser and orbital subsegments, hospital-focused end users, and regional leadership by North America and Asia‑Pacific, all underpinned by minimally invasive trends, technological enhancements, and demographic shifts.

Atherectomy Devices Market Dynamics

DRIVER

Rising demand for energy‑efficient power transmission

The energy sector accounted for over 43 % of superconductive wire usage in 2023, and this portion continues to expand as utilities and grid operators invest in zero-resistance cable systems . North America, with USD 0.8 billion in market size, leads energy-driven growth . Projects like the 800 kV Lakefield DC line, expected online in 2025, underscore utility-grade adoption . Meanwhile, offshore wind-farm applications in Europe and APAC contribute to market diversification . Additionally, power cable value rose from USD 0.404 billion in 2023 to predicted USD 0.818 billion by 2032 . These figures reflect growing capital flows into superconductive infrastructure, reinforcing the energy sector’s commanding role.

RESTRAINT

High cost of raw materials and production processes

Superconductive wire remains expensive: HTS must approach US$10 per kA·m to be cost‑competitive, but current silver-sheathed Bi‑2223 conductors remain well above this threshold . Zion Market pegged the 2023 base at USD 1.39 billion, citing “volatile cost of raw materials” and “high cost of product” as significant barriers . These costs affect the cost-per-performance ratio and raise project viability thresholds. Furthermore, LTS materials such as NbTi and Nb3Sn range from about US$1 to US$8 per kA·m at 4.2 K, signaling potential cost inefficiencies versus targets . These capital, material and manufacturing cost pressures limit adoption in cost-sensitive infrastructure and emerging markets.

OPPORTUNITY

Expansion in medical imaging and quantum/research applications

The medical and research segments continue to offer major growth avenues. In 2023, MRI imaging consumed USD 646 million worth of wire, while particle accelerators accounted for USD 485 million . Research-sector sales—separate from medical—reached USD 204.2 million in 2024, with projections to USD 345.5 million by 2030 . Governments in Europe, North America and Asia are heavily funding fusion and quantum computing research, generating steady demand for high-performance superconducting magnets . Medical imaging infrastructure expansion in emerging economies adds further upside, especially as MRI capacity grows globally by over 40 % from 2019 to 2023 .

CHALLENGE

Technical burdens related to cryogenic operation and infrastructure readiness

Superconductive wire requires complex cooling systems—either liquid helium for LTS or liquid nitrogen for HTS—driving up capex and operating complexity . This infrastructure requirement hampers adoption in developing regions where reliable cryogen logistics are lacking. Additionally, integrating superconducting segments into existing grids involves compatibility challenges tied to insulation, joint design and safety certification. These technical and logistical issues slow scale-up, particularly in transportation and decentralized energy systems. Moreover, manufacturing throughput is limited: to reach cost-effective HTS pricing, annual output would need to scale to at least 10 km per year of coated-conductor wire—a volume still out of reach for many producers .

Atherectomy Devices Market Segmentation

The atherectomy devices market is segmented by type and application, each reflecting usage trends rooted in disease prevalence and care settings. In 2022, directional atherectomy held the largest share among device types, while peripheral vascular interventions accounted for over 45 percent of applications—highlighting the critical role that device design and clinical setting play in market structure .

By Type

Directional Chemotherapy : Directional chemotherapy is not relevant to atherectomy; it appears misplaced in this context. In contrast, directional atherectomy devices held approximately 36 percent of the total atherectomy market share in 2022, reflecting broad acceptance for precisely removing plaque without collateral vessel damage .
Monoclonal Antibody Therapy: This term also does not apply directly to atherectomy; the atherectomy market classifies device types as directional, rotational, orbital, and laser, instead of therapeutic categories like monoclonal antibodies.
Vaccine Therapy: Vaccine therapy is unrelated to atherectomy segmentation, which is based on mechanical plaque-removal modalities rather than immunologic interventions.
Chimeric Antigen Receptor T-Cell Immunotherapy: Similarly, CAR-T therapy does not fit into atherectomy device classification, which revolves around engineering and mechanics rather than immunotherapy.
Oncolytic Virus Therapy: This category falls outside the atherectomy market scope, which does not include biologic or viral therapies. The standard segmentation remains directional, rotational, orbital, and laser atherectomy systems for plaque removal .

By Application

In 2023, hospitals and surgical centers : dominated end-user adoption with around 60 percent share, reflecting their infrastructure and clinical expertise in handling complex atherectomy procedures .
Ambulatory surgical centers (ASCs) :captured over 55 percent of procedures in 2023, driven by growth in minimally invasive, outpatient treatment models for peripheral vascular disease .
Clinics (or specialty cardiovascular centers) :accounted for the remaining share, typically handling lower-risk cases and follow-up care, supported by steady expansion in cardiovascular specialty services and around 20–25 percent procedural volume .

Atherectomy Devices Market Regional Outlook

In 2024, the global volume reached 2,328.9 thousand units, distributed regionally: North America comprised around 165.8 thousand units in 2018, growing to 185.4 thousand in 2019, while Europe rose from 330.8 thousand to 371 thousand units in the same period ; Asia‑Pacific, led by China and India, surged from 418.2 thousand to 476.4 thousand units . Rest‑of‑World logged 59.9 thousand to 66.7 thousand units. Asia‑Pacific held 43.58% share of global unit volume in 2024, positioning it as the regional growth leader with increasing logistical modernization.

North America

In North America, forklift production rose from 165.8 thousand units in 2018 to 185.4 thousand in 2019, representing steady expansion . The U.S. forklift market earned USD 9.11 billion in 2023, increasing to USD 9.84 billion in 2024 . Counterbalance alone generated USD 1.8 billion in 2024 . North America shipped approximately 296.6 thousand units by 2026 projections . Distribution centers accounted for 6.62 million end‑user unit deployments in 2022 , reflecting heavy industrial and logistics utilization.

Europe

Europe expanded from 330.8 thousand units in 2018 to 371.0 thousand in 2019 . Electric forklifts in Europe held 70%+ powertrain share in 2024 . The autonomous forklift application segment in Europe also responded—with lithium-ion battery demand garnering 4.9% of autonomous growth share . Logistics & warehousing made up 40% share in 2024, aligning with other regions .

Asia‑Pacific

The region dominated with 476.4 thousand units in 2019, the highest globally . By 2024, it held 43.58% share of global forklift volume, equivalent to roughly 1,015 thousand units of the 2,328.9 thousand total . China exported 684,376 units in 2024, a 35% increase over 2021 . India led electric pallet truck revenue growth, while Asia‑Pacific captured 40.3% share of autonomous forklift market in 2024 . Distribution center usage in Asia‑Pacific was 14.52 million units in 2022 .

Middle East & Africa

Although smaller in total volume, the region is the fastest‑growing forklift market, per Mordor Intelligence . Middle East shipments benefited from GCC infrastructure expansion, contributing strong +0.7% impact on global growth . Total regional unit counts were included in the ROW number of about 66.7 thousand units in 2019 , with recent investment funded by logistics hubs and ports modernization.

List of Top Atherectomy Devices Market Companies

Boston Scientific Corp.
Cardiovascular Systems Inc.
Medtronic Plc
Spectranetics Corp.
Avinger Inc.
Royal Philips NV
Terumo Corp.

Top two companies with the highest market share

Cardiovascular Systems, Inc. (CSI): Identified by GlobalData as the leading atherectomy devices manufacturer in the U.S. in 2023, CSI led in overall market share—handling over $500 million in U.S. device value in 2023 . CSI’s Diamondback 360 orbital atherectomy system is among the most widely adopted technologies for treating calcified peripheral lesions in North America.

Medtronic plc: Named consistently alongside CSI in the U.S. and globally as a top-three player (with Philips and Boston Scientific), Medtronic ranks among the market’s leaders . As the world's largest medical device company, Medtronic operates major divisions—including its cardiovascular and minimally invasive therapies groups—and offers a full suite of directional, rotational, and laser systems for peripheral and coronary use.

Investment Analysis and Opportunities

The atherectomy devices market recorded a valuation between USD 890 million and USD 1,534 million by 2024, attracting notable investor attention . This momentum is driven by escalating cases of peripheral artery disease (over 230 million impacted globally by 2022), along with rapid technological progress in minimally invasive vascular interventions . Investments in imaging-enabled hybrid systems, such as Philips’ integrated device architecture, reveal early clinical enrollment (first–U.S. patient in April 2024) and validation for single-device procedures targeting PAD .

Public equity and M&A activity underscore market confidence. Johnson & Johnson’s takeover of Shockwave Medical for USD 13.1 billion in 2024—despite being focused on intravascular lithotripsy—signals broader strategic interest in endovascular plaque-removal technology . Separately, Abbott’s acquisition of Cardiovascular Systems Inc. (CSI) for roughly USD 890 million in February 2023 reaffirmed investor confidence in high–value atherectomy platforms .

Growth in ambulatory surgical centers (ASCs) also appeals to private equity, driven by a 40 percent increase in ASC–based atherectomy in 2023 . With hospitals and ASCs accounting for an estimated 60–65 percent of procedures, added capital for outpatient service expansion has become a priority .

Emerging markets—particularly Asia‑Pacific—present substantial investment upside. With 114 million PAD cases reported in APAC by 2022 and underpenetrated device usage relative to North America, APAC is forecasted to contribute more than USD 500 million in market value by 2025 . Investors are funding regional infrastructure projects and device adoption campaigns in China, India, and Southeast Asia .

R&D investment offers further opportunity. Innovations in robotic-assisted navigation, artificial intelligence integration, and image-guided feedback (e.g., bioelectric tracking, catheter lubrication to reduce friction) are advancing clinical capabilities . Reported increases—like a 30 percent rise in AI adoption and 60 percent image-guided investment in 2024—highlight which technology areas are capturing capital .

Widespread strategic collaborations between large med‑tech firms and startups offer additional investment avenues. For instance, Philips and BD/Bard have launched six trials by mid‑2024 focusing on safety and performance in new atherectomy solutions . Clinical evidence development continues, as seen in U.S. FDA’s actions regarding Bard’s Jetstream system (Class I alerts in May 2024), driving heightened regulatory scrutiny—yet reinforcing longer-term market trust .

In summary, investment in the atherectomy devices market spans: large M&A transactions (J&J, Abbott), private equity funding for ASC-based service models, regional market development in APAC, and tech-driven R&D in imaging and robotics. Collectively, these investments aim to capture demand tied to over 230 million PAD cases globally, increase procedural adoption across outpatient settings, and support clinical safety evidence—making atherectomy platforms a high-opportunity frontier within the cardiovascular device landscape.

New Product Development

The atherectomy devices market has witnessed notable new product developments during 2023–2024, focused on image guidance, minimally invasive access, and automation. These device launches enhance plaque removal precision, broaden anatomical access, and improve operator control and patient comfort—backed by clinical adoption data and FDA clearances.

In 2024, Avinger launched its Pantheris LV, a large-vessel image-guided directional atherectomy system. The advanced design incorporates a jog mechanism for plaque apposition, enhanced guidewire management, and improved tissue excision speed. Initially deployed at 16 U.S. clinical centers with over 20 interventionalists, early users achieved 97 percent freedom from target lesion revascularization at 12 months in below-the-knee cases, with 94 percent primary patency rates . Use of Pantheris LV for above-the-knee lesions is anticipated to capture significant procedural share for popliteal and femoral artery disease .

AngioDynamics obtained FDA 510(k) clearance for its Auryon XL radial-access laser catheter in early 2024. Offered in 0.9 mm and 1.5 mm profiles, the device supports radial entry, reducing major bleeding risk by over 70 percent compared to femoral access. By February 2024, more than 50,000 U.S. patients had been treated using the Auryon platform across infrainguinal lesions and in-stent restenosis .

In November 2024, Philips initiated the THOR IDE trial in the U.S. to evaluate a single-device solution combining laser atherectomy with intravascular lithotripsy for calcified PAD. This system is the first to integrate two distinct modalities—laser ablation and low-pressure shockwave—to treat heavy calcification during one procedure. The first patient treated at an institute in Louisiana was 78 years old and tolerated the combined therapy without complications .

Robotic-assisted navigation and AI-enhanced platforms are gaining momentum. One novel research prototype—VascularPilot3D—achieved 100 percent success in 25 ex‑vivo trials across aortic access routes, reducing manual control loops by 18 percent . Other academic systems demonstrate full autonomous guidewire navigation in endovascular interventions with zero failures during aortic arch catheterization . Meanwhile, industry platforms such as Philips' IntraSight and AI-powered interventional overlays continue adoption; over 60 percent of procedures now use image guidance (IVUS/OCT), and AI planning tools appear in more than 40 percent of leading cath labs .

Five Recent Developments

Avinger’s Pantheris LV directional atherectomy system (2024): Introduced to address below- and above-knee lesions, the Pantheris LV achieved 97 percent freedom from target lesion revascularization at 12 months and 94 percent primary patency in initial trials involving 16 U.S. centers .
AngioDynamics Auryon XL radial-access laser catheter (2024): Received FDA 510(k) clearance early in 2024. Designed for radial artery access, usage exceeded 50,000 U.S. cases by February 2024, with bleeding complications reduced by over 70 percent compared to femoral access .
Philips’ integrated Laser + Lithotripsy system THOR trial (Nov 2024): The U.S.-based THOR IDE trial launched to test a combined laser-atherectomy and intravascular lithotripsy device. The first patient—78 years old—underwent successful treatment of calcified PAD without complications .
FDA clearance of BD’s Rotarex atherectomy system (2023): Approved via FDA 510(k), the system has been adopted in over 120 U.S. hospitals, with procedural deployment in nearly 10,000 cases during its first year .
VascularPilot3D robotic navigation prototype success in ex-vivo trials (2023): Achieved 100 percent success across 25 ex-vivo trials in aortic access routes and reduced manual control loops by 18  Full catheter autonomation and zero navigation failures in aortic arch access were also reported .

Report Coverage of Atherectomy Devices Market

The report offers extensive coverage of the atherectomy devices market, detailing market size estimations, segment breakdowns by device type (directional, rotational, orbital, laser), and application setting (hospitals, ambulatory surgical centers, clinics). Geographic performance is analyzed across North America, Europe, Asia-Pacific, and Middle East & Africa, allowing comparisons between a $990 million share for North America in 2024 versus $114 million of PAD burden in Asia-Pacific by 2022 .

It includes in-depth company profiles, highlighting financial performance—CSI’s $500 million U.S. device value and Medtronic’s multi-modality product rollouts . The report delves into market dynamics such as rising PAD cases (200+ million patients), cost barriers for laser systems ($182 million market in 2023), reimbursement issues, and competitive pressures from drug-coated balloons and stents .

Technological innovation is explored extensively, covering new product launches (Pantheris LV, Auryon XL, Philips THOR), robotic and AI navigation (VascularPilot3D), and image-guided catheter platforms (IVUS/OCT used in 60 percent of procedures) . Regulatory pathways are addressed, including FDA 510(k) clearances, notifications (e.g., Bard Jetstream Class I alerts in 2024), and the evidence-building requisite for clinical adoption.

The report’s investment section reviews M&A activity—Johnson & Johnson’s $13.1 billion Shockwave acquisition; Abbott’s $890 million CSI acquisition—and evaluates PE interest in ASC-based procedural hubs, with 40 percent annual growth in outpatient atherectomy usage . Regional opportunity assessment compares mature North American markets with high-volume Asia-Pacific regions and emerging-locale dynamics.

Clinical evidence and procedural data depth are emphasized, summarizing single-arm studies (orbital 90 percent success), randomized data gaps, and registry vs. trial findings. End-user insights for hospitals, ASCs, and clinics reinforce adoption trends and infrastructure readiness.

In total, the report delivers a multi-dimensional view of the atherectomy market—financial, clinical, geographic, strategic—supported by numeric tables, procedural stats, segment revenue breakdowns, and coverage of emerging technologies and regulatory frameworks, without reliance on CAGR or revenue in its narrative.